Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05622721 · ClinicalTrials.gov registry record
REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs
A clinical trial of Dysbiosis and Clostridium Difficile, sponsored by University of Pennsylvania.
- Active
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT05622721 is a study of Dysbiosis and Clostridium Difficile that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 200 participants, above the 99-participant average among 13 other Dysbiosis trials with a reported enrollment target (102% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05622721, a study of Dysbiosis and Clostridium Difficile, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Antimicrobial therapy can lead to disruption of the gut microbiome and infection with Clostridioides difficile, a disease associated with high morbidity and mortality, particularly among the elderly. Drawing on observations that pet ownership and close contact with pets are protective against colonization with C. difficile and recurrence of C. difficile infection, the proposed study will test the hypothesis that microbiota that provide colonization resistance against C. difficile are shared between patients and their pets and that pet contact can mitigate antimicrobial-associated gut dysbiosis and the risk of C. difficile infection. This study will further define epidemiologic and pathophysiologic characteristics of C. difficile infection and gut microbiome dysbiosis that could enhance therapeutic options for these conditions, potentially through non-invasive interventions involving animal contact.
Conditions Studied
Study Locations (1)
Pennsylvania
- The Robert Schattner Center, University of Pennsylvania, School of Dental Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-05-30 |
| Est. Completion | 2026-05-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05622721
The ClinicalTrials.gov registry entry for NCT05622721 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 99-participant average among 13 other Dysbiosis trials with a reported enrollment target (102% higher). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Dysbiosis appearing as the primary indexed condition, and to 0 interventions.
NCT05622721 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05622721 about?
NCT05622721 is a clinical study titled "REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs". Antimicrobial therapy can lead to disruption of the gut microbiome and infection with Clostridioides difficile, a disease associated with high morbidity and mortality, particularly among the elderly. Drawing on observations that pet ownership and close contact with pets are protective against coloni...
What is the current status of trial NCT05622721?
This trial is currently active not recruiting. The enrollment target is 200 participants. The study started on 2022-05-30. Estimated completion is 2026-05-01.
What conditions does trial NCT05622721 study?
This clinical trial studies the following conditions: Dysbiosis, Clostridium Difficile, Antibiotic-Associated Colitis, Pet-Human Bonding.
Who is sponsoring clinical trial NCT05622721?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05622721 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dysbiosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Peanut Butter on Gut and Metabolic Health
RECRUITING · NA
-
Personalized GI Motility Responses to Diet
RECRUITING · NA
-
Effect of Lentils and Chickpeas on Gut Microbiome and Metabolic Health
RECRUITING · NA
-
A Study of Healthy Microbiome, Healthy Mind
RECRUITING · NA
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Effect of Watermelon on Gut and Cardiometabolic Health
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.